PLATFORMS Signal 350
Paul Conyngham launches Gamgee, a Y Combinator-backed startup for personalized mRNA dog cancer vaccines
↗
The Australian entrepreneur who claimed to use ChatGPT to design a cancer vaccine for his dog has formalized the effort into Gamgee, a Y Combinator-backed startup offering personalized mRNA cancer vaccines for dogs with stated ambitions to expand to humans.
The startup's scientific foundation rests on a single dog whose improvement cannot be clearly attributed to the mRNA vaccine because it was administered alongside another therapy, and researchers have said the original story overcredited AI's role. Y Combinator's backing nonetheless gives Gamgee institutional credibility and resources to pursue clinical trials, raising questions about how venture incubators evaluate AI-adjacent biotech claims with thin evidentiary bases.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
Paul Conyngham launched Gamgee to offer personalized mRNA cancer vaccines for dogs, with stated plans to expand to personalized treatments for humans.
The startup's single documented case involved concurrent therapy, making it impossible to attribute tumor reduction to the mRNA vaccine alone, and researchers said the original story gave AI too much credit.
Gamgee is backed by Y Combinator, is recruiting for clinical trials in Australia, and claims roughly 75 per cent tumor reduction in its first case.
THE CLUSTER